Subscribe to Newsletter
Subspecialties Retina

My Retina, My Rules

When it comes to treating wet age-related macular degeneration (AMD), ophthalmologists are more likely to choose more expensive anti-VGEF agents and less likely to choose treat-and-extend dosing regimens for themselves, compared with what they might prescribe for patients (1).

Researchers based at the Rutgers-Robert Wood Johnson Medical School in New Jersey, performed a survey of 200 retina specialists in the USA. They were split in to two groups – the first was presented with a hypothetical 70-year old patient, the second group was told that they were that patient. The symptoms were wet AMD with 20/100 visual acuity in the left eye, choroidal neovascularization, subretinal fluid, cystoid macular edema, and high-risk drusen in the right eye. Respondents then gave their recommendations on dosing regimen and on which anti-VEGF treatment they would use: aflibercept, bevacizumab, or ranibizumab.

0914-203-fig.1

Figure 1. Prescribed therapy and dosing regimen chosen by US-based ophthalmologists for

administration to either themselves (if they had wet AMD) or a hypothetical 70-year old patient

(with the same symptoms).

So what choices did they make? When it came to the hypothetical patient, just over half of the specialists recommended using bevacizumab. Those treating themselves had less of a preference for bevacizumab, being split equally across the three drugs – demonstrating a slight, but significant preference for the costlier compounds. Dosing regimen choice differed between the groups too – 73 percent said they would treat and extend in the patient, but only 63 percent would do the same if they were the patient.

It’s a small survey (so take the results with a pinch of salt), but the results tell an interesting story: generally, it’s cheaper drugs for the patient, with the longest possible intervals (understandable in a country with expensive health insurance and co-pays for premium medications), and more expensive and potentially more effective drugs for the eyecare professionals, that are more likely to be administered to a regimen that minimizes the risk of visual acuity loss (at the cost of more injections).

If you had AMD, would you follow the regimen you recommend to your patients? If not, why not?

Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. K.W. Jeng, J. Wilgucki, S. Halperin, et al., “Retina specialists treating age-related macular degeneration recommend different approaches for patients than they would choose for themselves”, Retina, 34, 1796–1801 (2014). doi:10.1097/IAE.0000000000000182.
About the Author
Roisin McGuigan

I have an extensive academic background in the life sciences, having studied forensic biology and human medical genetics in my time at Strathclyde and Glasgow Universities. My research, data presentation and bioinformatics skills plus my ‘wet lab’ experience have been a superb grounding for my role as a deputy editor at Texere Publishing. The job allows me to utilize my hard-learned academic skills and experience in my current position within an exciting and contemporary publishing company.

Related Product Profiles
Uncover the Unique DNA of SPECTRALIS®

| Contributed by Heidelberg Engineering

Subspecialties Retina
ForeseeHome® – remote monitoring to help detect wet AMD earlier and improve outcomes

| Contributed by Notal Vision

Product Profiles

Access our product directory to see the latest products and services from our industry partners

Here
Most Popular
Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: